28 January 2016 - Amgen Canada Inc. today announced that Health Canada has approved Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.

For more details, go to: http://www.newswire.ca/news-releases/health-canada-approves-amgens-new-multiple-myeloma-treatment-kyprolis-carfilzomib-566813391.html